3/26
05:49 am
allo
Allogene Therapeutics (ALLO) was upgraded by Truist Financial Corporation to "strong-buy".
Medium
Report
Allogene Therapeutics (ALLO) was upgraded by Truist Financial Corporation to "strong-buy".
3/13
02:48 pm
allo
Allogene Therapeutics (ALLO) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.
Neutral
Report
Allogene Therapeutics (ALLO) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.
3/13
12:38 pm
allo
Allogene Therapeutics (ALLO) had its price target raised by Piper Sandler from $7.00 to $8.00. They now have an "overweight" rating on the stock.
Low
Report
Allogene Therapeutics (ALLO) had its price target raised by Piper Sandler from $7.00 to $8.00. They now have an "overweight" rating on the stock.
3/12
11:19 pm
allo
Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlights: Financial Stability and ... [Yahoo! Finance]
Medium
Report
Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlights: Financial Stability and ... [Yahoo! Finance]
3/12
10:04 pm
allo
Allogene Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Allogene Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
3/12
04:10 pm
allo
Allogene Therapeutics GAAP EPS of -$0.17 beats by $0.05 [Seeking Alpha]
Medium
Report
Allogene Therapeutics GAAP EPS of -$0.17 beats by $0.05 [Seeking Alpha]
3/12
04:02 pm
allo
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Medium
Report
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
3/3
10:52 pm
allo
Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen [Yahoo! Finance]
Neutral
Report
Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen [Yahoo! Finance]
3/2
08:54 am
allo
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update [Yahoo! Finance]
Low
Report
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update [Yahoo! Finance]
3/2
08:30 am
allo
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
Low
Report
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
2/22
02:02 am
allo
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at
Wall Str
Low
Report
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at
Wall Str
2/5
08:30 am
allo
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Medium
Report
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
1/29
11:12 pm
allo
??·?????????????????2035????1,831????????????????? [CNET News]
High
Report
??·?????????????????2035????1,831????????????????? [CNET News]
1/9
11:12 am
allo
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? [Yahoo! Finance]
Medium
Report
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? [Yahoo! Finance]
1/9
08:42 am
allo
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at Citizens Jmp from a "market perform" rating to a "mkt outperform" rating. They now have a $5.00 price target on the stock.
Medium
Report
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at Citizens Jmp from a "market perform" rating to a "mkt outperform" rating. They now have a $5.00 price target on the stock.
1/9
07:00 am
allo
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at Citigroup Inc. from a "market perform" rating to an "outperform" rating.
Medium
Report
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at Citigroup Inc. from a "market perform" rating to an "outperform" rating.
1/9
06:10 am
allo
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Medium
Report
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/8
09:06 am
allo
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T [Yahoo! Finance]
Low
Report
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T [Yahoo! Finance]
1/8
08:30 am
allo
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
Low
Report
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
1/7
09:07 am
allo
Allogene Therapeutics (NASDAQ:ALLO) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Medium
Report
Allogene Therapeutics (NASDAQ:ALLO) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.